Skip to main content

Neurodegenerative disorders

20-12-2018 | Motor neuron diseases | News | Article

Cannabinoid spray shows anti-spasticity efficacy in motor neuron disease

The oromucosal cannabinoid spray nabiximols has had a positive effect on spasticity symptoms in patients with motor neuron disease in a proof-of-concept trial.


Lancet Neurol 2018; doi:10.1016/ S1474-4422(18)30406-X

Lancet Neurol 2018; doi:10.1016/ S1474-4422(18)30493-9

13-12-2018 | Neurology | Main feed | News

Biomarkers predict cognitive impairment risk

US researchers have used population-based data to predict an individual’s absolute risk of developing cognitive impairment according to imaging-based biomarkers of amyloid and neuronal injury.


Ann Neurol 2018; doi:10.1002/ana.25388

06-12-2018 | Alzheimer's disease | News | Article

Factors predicting misclassification in brief cognitive testing identified

Over a third of patients tested for dementia in the primary care setting may be misclassified due to specific biases in commonly used brief cognitive tests, study findings indicate.


Neurol Clin Pract 2018; doi:10.1212/CPJ.0000000000000566

29-11-2018 | Alzheimer's disease | News | Article

Global burden of dementia estimated

The number of people living with dementia globally has more than doubled between 1990 and 2016, estimates the Global Burden of Disease Study 2016.


Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30403-4

Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30456-3

22-11-2018 | Alzheimer's disease | Highlight | Article

Editor's pick

Most patients with Down’s syndrome will have dementia at the time of death

Dementia is the proximate cause of death in 70% of older adults with Down’s syndrome, show findings from a large community-based study published in JAMA Neurology.


JAMA Neurol 2018; doi:10.1001/jamaneurol.2018.3616

JAMA Neurol 2018; doi:10.1001/jamaneurol.2018.3443

15-11-2018 | Alzheimer's disease | News | Article

CSF neurofilament light a ‘preferred’ biomarker for MCI progression

Elevated cerebrospinal fluid neurofilament light levels are associated with an increased risk of mild cognitive impairment, indicate findings from a population-based study.


JAMA Neurol 2018; doi:10.1001/jamaneurol.2018.3459

01-11-2018 | Parkinson's disease | News | Article

Dopamine to levodopa-carbidopa switch reduces impulse control disorders in PD

Switching from dopamine agonists to levodopa-carbidopa slow-release formulations reduces impulse control disorders in patients with Parkinson’s disease, shows a multicentre study.


J Neurol Neurosurg Psychiatry 2018; doi:10.1136/jnnp-2018-318942

J Neurol Neurosurg Psychiatry 2018; doi:10.1136/jnnp-2018-319375

11-10-2018 | Neurology | News | Article

Editor's pick

Anticoagulants could stave off increased risk of dementia associated with AF

Study findings show an increased risk of dementia in older people with atrial fibrillation and support the use of anticoagulants to reduce the likelihood.


Neurology 2018; doi:10.1212/WNL.0000000000006456

Neurology 2018; doi:10.1212/WNL.0000000000006458

04-10-2018 | Neurology | News | Article

Global burden of Parkinson’s disease is on the rise

The global burden of Parkinson’s disease has more than doubled over the past 26 years, show findings from the Global Burden of Disease Study 2016.


Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30295-3

Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30355-7

20-09-2018 | Alzheimer's disease | News | Article

Flortaucipir PET discriminates AD from other neurodegenerative disorders

The positron emission tomography tracer [18F]flortaucipir could be a useful test for distinguishing Alzheimer’s disease from other neurodegenerative disorders, say researchers.


JAMA 2018; 320: 1151–1162

06-09-2018 | Alzheimer's disease | News | Article

Biomarkers identified for diagnosing AD in patients with Down syndrome

Plasma neurofilament light protein concentrations and cerebrospinal fluid biomarkers are effective for diagnosing Alzheimer’s disease in patients with Down syndrome, say researchers.


Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30285-0
Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30293-X

03-08-2018 | Parkinson's disease | News | Article

Apomorphine infusion reduces ‘off time’ in patients with Parkinson’s disease

Subcutaneous apomorphine infusion meaningfully reduces the time in which a patient’s medication is not working optimally and parkinsonian symptoms return, reports the placebo-controlled, multicentre TOLEDO trial.


Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30239-4
Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30284-9

27-07-2018 | Parkinson's disease | News | Article

Editor's pick

Occipital GABA levels reduced in Parkinson’s patients with visual hallucinations

Reduced levels of γ-aminobutyric acid in the primary visual cortex are linked to visual hallucinations in patients with Parkinson’s disease, study findings indicate.


Neurology 2018; doi:10.1212/WNL.0000000000006007
Neurology 2018; doi:10.1212/WNL.0000000000005985

15-02-2017 | Parkinson's disease | Main feed | Article

Blood-based NfL differentiates PD and parkinsonian disorders

A simple blood test for neurofilament light chain protein could help physicians distinguish atypical parkinsonian disorders from Parkinson’s disease, study findings show.


Neurology 2017; Advance online publication


03-02-2017 | Neurodegeneration | News | Article

News in brief

Mentally stimulating activities in later life may stave off MCI

Regularly engaging in mentally stimulating activities in later life could help reduce the risk of mild cognitive impairment, research suggests.


JAMA 2017; Advance online publication

01-02-2017 | Neurodegeneration | News | Article

News in brief

No go for ozanezumab treatment in ALS

Ozanezumab has failed to show efficacy for the treatment of amyotrophic lateral sclerosis in a phase II study, making neurite outgrowth inhibitor A potentially redundant as a treatment target.

05-01-2017 | Neurodegeneration | News | Article

Living close to major roads increases dementia risk

Living close to major roads is associated with an increased risk for dementia, but not for Parkinson’s disease or multiple sclerosis, study findings reported in The Lancet show.


Lancet 2017; Advance online publication

22-12-2016 | Alzheimer's disease | News | Article

News in brief

Protein in urine linked to dementia risk

Albuminuria is modestly associated with the risk for dementia, researchers report in findings supporting the view that cognitive decline and renal dysfunction may be linked.

21-12-2016 | Alzheimer's disease | News | Article

Editor's pick

Anti-tau vaccine for AD shows ‘exceptional immunogenicity’

A first-in-human clinical trial of an active vaccine targeting pathologic tau protein in patients with Alzheimer’s disease has shown the vaccine elicits a well-tolerated, strong, and specific immune response.


Lancet Neurol 2016; Advance online publication

13-12-2016 | Alzheimer's disease | News | Article

Gender and ethnicity affect protective role of statins against AD

The potential reduction in Alzheimer’s disease risk afforded by high use of statins varies by statin type, gender, and ethnicity, report researchers.


JAMA Neurol 2016; Advance online publication

image credits